#begin document (nw/wsj/03/wsj_0318); part 000
nw/wsj/03/wsj_0318   0    0          Lyphomed   NNP   (TOP(S(NP(NP(NP*       -    -   -   -        (ORG*   (ARG0*        *              *   -
nw/wsj/03/wsj_0318   0    1              Inc.   NNP                  *)      -    -   -   -            *)       *        *              *   -
nw/wsj/03/wsj_0318   0    2                 ,     ,                  *       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0    3          Rosemont   NNP            (NP(NP*)      -    -   -   -         (GPE)       *        *              *   -
nw/wsj/03/wsj_0318   0    4                 ,     ,                  *       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0    5              Ill.   NNP              (NP*))      -    -   -   -         (GPE)       *        *              *   -
nw/wsj/03/wsj_0318   0    6                 ,     ,                  *)      -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0    7               and    CC                  *       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0    8             Medco   NNP            (NP(NP*       -    -   -   -        (ORG*        *        *              *   -
nw/wsj/03/wsj_0318   0    9          Research   NNP                  *       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   10              Inc.   NNP                  *)      -    -   -   -            *)       *        *              *   -
nw/wsj/03/wsj_0318   0   11                 ,     ,                  *       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   12               Los   NNP               (NP*       -    -   -   -        (GPE*        *        *              *   -
nw/wsj/03/wsj_0318   0   13           Angeles   NNP                  *)      -    -   -   -            *)       *        *              *   -
nw/wsj/03/wsj_0318   0   14                 ,     ,                 *))      -    -   -   -            *        *)       *              *   -
nw/wsj/03/wsj_0318   0   15              said   VBD               (VP*      say  01   -   -            *      (V*)       *              *   -
nw/wsj/03/wsj_0318   0   16               the    DT        (SBAR(S(NP*       -    -   -   -        (ORG*   (ARG1*   (ARG0*              *   -
nw/wsj/03/wsj_0318   0   17              Food   NNP              (NML*       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   18               and    CC                  *       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   19              Drug   NNP                  *)      -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   20    Administration   NNP                  *)      -    -   -   -            *)       *        *)             *   -
nw/wsj/03/wsj_0318   0   21           granted   VBD               (VP*    grant  01   -   -            *        *      (V*)             *   -
nw/wsj/03/wsj_0318   0   22              full    JJ            (NP(NP*       -    -   -   -            *        *   (ARG1*              *   -
nw/wsj/03/wsj_0318   0   23         marketing    NN                  *       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   24          approval    NN                  *)      -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   25               for    IN               (PP*       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   26                 a    DT            (NP(NP*       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   27               new    JJ                  *       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   28              drug    NN                  *)      -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   29               for    IN               (PP*       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   30               the    DT            (NP(NP*       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   31         treatment    NN                  *)      -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   32                of    IN               (PP*       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   33                 a    DT            (NP(NP*       -    -   -   -            *        *        *     (ARGM-ADV*   -
nw/wsj/03/wsj_0318   0   34         condition    NN                  *)      -    -   -   -            *        *        *              *)  -
nw/wsj/03/wsj_0318   0   35                in    IN        (SBAR(WHPP*       -    -   -   -            *        *        *   (R-ARGM-ADV*   -
nw/wsj/03/wsj_0318   0   36             which   WDT            (WHNP*))      -    -   -   -            *        *        *              *)  -
nw/wsj/03/wsj_0318   0   37               the    DT             (S(NP*       -    -   -   -            *        *        *         (ARG1*   -
nw/wsj/03/wsj_0318   0   38             heart    NN                  *)      -    -   -   -            *        *        *              *)  -
nw/wsj/03/wsj_0318   0   39             beats   VBZ               (VP*     beat  01   -   -            *        *        *            (V*)  -
nw/wsj/03/wsj_0318   0   40           between    IN         (NP(NP(QP*       -    -   -   -   (CARDINAL*        *        *     (ARGM-ADV*   -
nw/wsj/03/wsj_0318   0   41              150     CD                  *       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   42               and    CC                  *       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   43              200     CD                  *)      -    -   -   -            *)       *        *              *   -
nw/wsj/03/wsj_0318   0   44             beats   NNS                  *)      -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   45                 a    DT               (NP*       -    -   -   -            *        *        *              *   -
nw/wsj/03/wsj_0318   0   46            minute    NN   *))))))))))))))))      -    -   -   -            *        *)       *)             *)  -
nw/wsj/03/wsj_0318   0   47                 .     .                 *))      -    -   -   -            *        *        *              *   -

nw/wsj/03/wsj_0318   0    0                 The    DT  (TOP(S(NP(NP*      -    -   -   -   *   (ARG1*   (ARG0*   -
nw/wsj/03/wsj_0318   0    1           condition    NN              *)     -    -   -   -   *        *)       *   -
nw/wsj/03/wsj_0318   0    2                   ,     ,              *      -    -   -   -   *        *        *   -
nw/wsj/03/wsj_0318   0    3               known   VBN           (VP*    know  01   2   -   *      (V*)       *   -
nw/wsj/03/wsj_0318   0    4                  as    IN           (PP*      -    -   -   -   *   (ARG2*        *   -
nw/wsj/03/wsj_0318   0    5          paroxysmal    JJ           (NP*      -    -   -   -   *        *        *   -
nw/wsj/03/wsj_0318   0    6    supraventricular    JJ              *      -    -   -   -   *        *        *   -
nw/wsj/03/wsj_0318   0    7         tachycardia    NN            *)))     -    -   -   -   *        *)       *   -
nw/wsj/03/wsj_0318   0    8                   ,     ,              *)     -    -   -   -   *        *        *)  -
nw/wsj/03/wsj_0318   0    9               leads   VBZ           (VP*    lead  03   -   -   *        *      (V*)  -
nw/wsj/03/wsj_0318   0   10                  to    IN           (PP*      -    -   -   -   *        *   (ARG2*   -
nw/wsj/03/wsj_0318   0   11           dizziness    NN           (NP*      -    -   -   -   *        *        *   -
nw/wsj/03/wsj_0318   0   12                 and    CC              *      -    -   -   -   *        *        *   -
nw/wsj/03/wsj_0318   0   13            fainting    NN            *)))     -    -   -   -   *        *        *)  -
nw/wsj/03/wsj_0318   0   14                   .     .             *))     -    -   -   -   *        *        *   -

nw/wsj/03/wsj_0318   0   0        The    DT  (TOP(S(NP*      -    -   -   -            *       (ARG1*   -
nw/wsj/03/wsj_0318   0   1    typical    JJ           *      -    -   -   -            *            *   -
nw/wsj/03/wsj_0318   0   2    healthy    JJ           *      -    -   -   -            *            *   -
nw/wsj/03/wsj_0318   0   3      heart    NN           *)     -    -   -   -            *            *)  -
nw/wsj/03/wsj_0318   0   4      beats   VBZ        (VP*    beat  01   -   -            *          (V*)  -
nw/wsj/03/wsj_0318   0   5        70     CD     (NP(NP*      -    -   -   -    (CARDINAL)  (ARGM-ADV*   -
nw/wsj/03/wsj_0318   0   6      times   NNS           *)     -    -   -   -            *            *   -
nw/wsj/03/wsj_0318   0   7          a    DT        (NP*      -    -   -   -            *            *   -
nw/wsj/03/wsj_0318   0   8     minute    NN         *)))     -    -   -   -            *            *)  -
nw/wsj/03/wsj_0318   0   9          .     .          *))     -    -   -   -            *            *   -

nw/wsj/03/wsj_0318   0    0          The    DT  (TOP(S(NP(NP*        -    -   -   -        *    (ARG1*       (ARG0*   -
nw/wsj/03/wsj_0318   0    1         drug    NN              *)       -    -   -   -        *         *)           *   -
nw/wsj/03/wsj_0318   0    2            ,     ,              *        -    -   -   -        *         *            *   -
nw/wsj/03/wsj_0318   0    3       called   VBN           (VP*      call  01   -   -        *       (V*)           *   -
nw/wsj/03/wsj_0318   0    4    adenocard    NN       (S(NP*)))       -    -   -   -        *    (ARG2*)           *   -
nw/wsj/03/wsj_0318   0    5            ,     ,              *)       -    -   -   -        *         *            *)  -
nw/wsj/03/wsj_0318   0    6      returns   VBZ           (VP*    return  03   -   -        *         *          (V*)  -
nw/wsj/03/wsj_0318   0    7          the    DT           (NP*        -    -   -   -        *         *       (ARG1*   -
nw/wsj/03/wsj_0318   0    8        heart    NN              *)       -    -   -   -        *         *            *)  -
nw/wsj/03/wsj_0318   0    9           to    IN           (PP*        -    -   -   -        *         *       (ARG2*   -
nw/wsj/03/wsj_0318   0   10            a    DT           (NP*        -    -   -   -        *         *            *   -
nw/wsj/03/wsj_0318   0   11       normal    JJ              *        -    -   -   -        *         *            *   -
nw/wsj/03/wsj_0318   0   12       rhythm    NN             *))       -    -   -   -        *         *            *)  -
nw/wsj/03/wsj_0318   0   13       within    IN           (PP*        -    -   -   -        *         *   (ARGM-TMP*   -
nw/wsj/03/wsj_0318   0   14      seconds   NNS          (NP*))       -    -   -   -    (TIME)        *            *)  -
nw/wsj/03/wsj_0318   0   15            ,     ,              *        -    -   -   -        *         *            *   -
nw/wsj/03/wsj_0318   0   16    according   VBG           (PP*        -    -   -   -        *         *   (ARGM-ADV*   -
nw/wsj/03/wsj_0318   0   17           to    IN           (PP*        -    -   -   -        *         *            *   -
nw/wsj/03/wsj_0318   0   18     Lyphomed   NNP        (NP*))))       -    -   -   -     (ORG)        *            *)  -
nw/wsj/03/wsj_0318   0   19            .     .             *))       -    -   -   -        *         *            *   -

nw/wsj/03/wsj_0318   0    0        Medco   NNP   (TOP(S(NP*         -    -   -   -   (ORG*   (ARG0*       (ARG0*   -
nw/wsj/03/wsj_0318   0    1     Research   NNP            *)        -    -   -   -       *)       *)           *)  -
nw/wsj/03/wsj_0318   0    2    developed   VBD      (VP(VP*    develop  02   -   -       *      (V*)           *   -
nw/wsj/03/wsj_0318   0    3          the    DT         (NP*         -    -   -   -       *   (ARG1*            *   -
nw/wsj/03/wsj_0318   0    4         drug    NN           *))        -    -   -   -       *        *)           *   -
nw/wsj/03/wsj_0318   0    5          and    CC            *         -    -   -   -       *        *            *   -
nw/wsj/03/wsj_0318   0    6     licensed   VBD         (VP*    license  01   1   -       *        *          (V*)  -
nw/wsj/03/wsj_0318   0    7           it   PRP         (NP*)        -    -   -   -       *        *       (ARG1*)  -
nw/wsj/03/wsj_0318   0    8           to    IN         (PP*         -    -   -   -       *        *       (ARG2*   -
nw/wsj/03/wsj_0318   0    9     Lyphomed   NNP        (NP*))        -    -   -   -    (ORG)       *            *)  -
nw/wsj/03/wsj_0318   0   10          for    IN         (PP*         -    -   -   -       *        *   (ARGM-PNC*   -
nw/wsj/03/wsj_0318   0   11         sale    NN      (NP(NP*)        -    -   -   -       *        *            *   -
nw/wsj/03/wsj_0318   0   12           in    IN         (PP*         -    -   -   -       *        *            *   -
nw/wsj/03/wsj_0318   0   13          the    DT      (NP(NP*         -    -   -   -       *        *            *   -
nw/wsj/03/wsj_0318   0   14         U.S.   NNP            *)        -    -   -   -    (GPE)       *            *   -
nw/wsj/03/wsj_0318   0   15          and    CC            *         -    -   -   -       *        *            *   -
nw/wsj/03/wsj_0318   0   16       Canada   NNP   (NP*)))))))        -    -   -   -    (GPE)       *            *)  -
nw/wsj/03/wsj_0318   0   17            .     .           *))        -    -   -   -       *        *            *   -

#end document
